M.D., MPH, FACP, Chief Scientific Officer, Thermo Fisher
Klaus Lindpaintner, MD, MPH, FACP serves as Chief Scientific Officer at Thermo Fisher Scientific, the world leader in oncology genomics companion testing products. Previously, he held senior positions at Hoffman-La Roche, where he spearheaded the company’s efforts in personalized health care; at SDIX, a specialty-antibody-focused biotechnology company; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institutions world-wide.
Democratizing Oncology Precision Medicine with NGS
Next-generation sequencing (NGS) enables analysis of hundreds of genes simultaneously, generating accurate, affordable genetic information. Our vision toward advancing precision genomics leverages Ion Torrent™ technology and Oncomine™ assays, offering an accessible NGS workflow to deliver targeted results across potentially relevant DNA and RNA biomarkers, and to do so with limited starting amounts of nucleic acid material.